Expression of CCR6 and CXCR6 by Gut-Derived CD4+/CD8α+ T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases

Godefroy, Emmanuelle; Alameddine, Joudy; Montassier, Emmanuel; Mathé, Justine; Desfrançois-Noël, Juliette; Marec, Nadège; Bossard, Céline; Jarry, Anne; Bridonneau, Chantal; Roy, Amandine Le; Sarrabayrouse, Guillaume; Kerdreux, Elise; Bourreille, Arnaud; Sokol, Harry; Jotereau, Francine; Altare, Frédéric

doi:10.1053/j.gastro.2018.06.078

Cited by 42 publications

(53 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, there is evidence that IL-10 exhibits a suppressive and modulatory action by downregulating the activation of the immune cells and co-stimulatory molecules, thus protecting from immune-related mucosal injury during the chronic stage in IBD. Deficiency in IL-10 receptor [42], as well as changes in the subset and in the number of Treg in colonic mucosa and blood, induce the development of severe IBD in mice and humans [41,43]. As obtained using longer administration periods [25], in the current experiment, the treatment with BC for 7 days reduced the increase of IL-10 gene expression in TNBS-induced colitis in mice.…”

Section: Discussionsupporting

confidence: 57%

The Prophylactic Use of Bovine Colostrum in a Murine Model of TNBS-Induced Colitis

Menchetti

Curone

Filipescu³

et al. 2020

Animals

View full text Add to dashboard Cite

Simple Summary: Colostrum is the first milk secreted by the mammary glands, and it is very rich in bioactive components. Recently, the importance of bovine colostrum (BC) as a nutraceutical product has been emerging with regards to gastrointestinal diseases. One of the most widespread gastrointestinal disorders is the inflammatory bowel disease (IBD), a multifactorial chronic condition that has a powerful impact on the social life of millions of people. Because current therapy protocols neither ensure complete recovery from IBD nor are free of secondary side effects, the present study assessed the impact of a short-term prophylactic oral administration of BC in a murine model of TNBS-induced colitis. BC administration was both well tolerated and did not induce any pathological symptoms. It considerably modulated the response to inflammation through modifications of the TLR4 and cytokines gene expression profiles as well as that of the intestinal microbiota. Although further studies are needed to develop a precise therapeutic protocol of BC administration, it seems to have the potential to be used as a natural supplement in the treatment of IBD.Abstract: This study investigated the effects of a short-term administration of bovine colostrum (BC) in a TNBS model of induced colitis. Colitis was induced by TNBS treatment after seven days of BC (BC group, n = 12) or saline (control group, n = 12) administration in mice. Clinical signs, histopathological characteristics, expression levels of Toll-like receptor 4 (TLR4), pro-and anti-inflammatory cytokines, and microbial composition were assessed. BC was well tolerated and did not induce any histological damage or clinical symptoms. After TNBS treatment, the BC group showed a reduction in body weight (BW) loss compared to Control (p < 0.05). Moreover, expression levels of TLR4 (p < 0.01), Interleukin-1β (IL-1β; p < 0.001), Interleukin-8 (IL-8; p < 0.001), and Interleukin-10 (IL-10; p < 0.001) were lower in mice administered with BC. Finally, Escherichia coli were higher (p < 0.05), while Enterococci (p < 0.001), Lactobacillus spp. (p < 0.001), and Bifidobacterium spp. (p < 0.05) were lower in Control than BC group. This study confirms that pre-treatment with BC modulates the expression of genes and the count of microbes involved in the etiopathogenesis of colitis.

show abstract

Section: Discussionsupporting

confidence: 57%

The Prophylactic Use of Bovine Colostrum in a Murine Model of TNBS-Induced Colitis

Menchetti

Curone

Filipescu³

et al. 2020

Animals

View full text Add to dashboard Cite

show abstract

“…A recent study discovered a new gut-derived T REG cell subpopulation, named DP8α, which could express both CD4 and CD8α. Among DP8α T cells, there were F. prauspecific T cells co-expressing CCR6 and CXCR6, decreased in inflammatory bowel disease (IBD) patients [26]. But the results haven't been verified in animals.…”

Section: Benefits From Crosstalk Between Clostridium Species and Intementioning

confidence: 98%

“…For instance, the diets enriched in different fibers, such as inulin, oligofructose, arabinoxylan, guar gum and resistant starch, all of which induced the enrichment of Clostridium cluster IV and XIVa representatives along with changed mucosal energy metabolism [63]. Additionally, dietary inulin-type fructans and arabinoxylan-oligosaccharides could not only directly promote the growth and reproduction of Clostridium species but also indirectly facilitate the acetate production from bifidobacterial strains fermentation to provide more substrates for Clostridium species to produce butyrate [26]. However, unreasonable doses and impertinent fibers would produce counterproductive results.…”

Section: Dietary Polysaccharidesmentioning

confidence: 99%

Clostridium species as probiotics: potentials and challenges

Guo

Zhang

et al. 2020

J Animal Sci Biotechnol

304

192

View full text Add to dashboard Cite

Clostridium species, as a predominant cluster of commensal bacteria in our gut, exert lots of salutary effects on our intestinal homeostasis. Up to now, Clostridium species have been reported to attenuate inflammation and allergic diseases effectively owing to their distinctive biological activities. Their cellular components and metabolites, like butyrate, secondary bile acids and indolepropionic acid, play a probiotic role primarily through energizing intestinal epithelial cells, strengthening intestinal barrier and interacting with immune system. In turn, our diets and physical state of body can shape unique pattern of Clostridium species in gut. In view of their salutary performances, Clostridium species have a huge potential as probiotics. However, there are still some nonnegligible risks and challenges in approaching application of them. Given this, this review summarized the researches involved in benefits and potential risks of Clostridium species to our health, in order to develop Clostridium species as novel probiotics for human health and animal production.

show abstract

“…Godefroy and co-workers in 2018 report a newly identified T cell subset named CD4 + /CD8α + or double positive 8 alpha cells (DP8α cells) which reportedly express CCR6 and proliferate when stimulated by a gut-inhabiting faecal microbe, Faecalibacterium prausnitzii, a firmicute of the Clostridium IV group. These microbes are said to be low in numbers in IBD patients but in healthy individuals they promote the release of the cytokine, IL-10 and inhibit T cell proliferation in a CD39-dependent pathway [65].…”

Section: The Effect Of Regulatory Treg Cells In Ibdmentioning

confidence: 99%

CCR6–CCL20 Axis in IBD: What Have We Learnt in the Last 20 Years?

Ranasinghe

Eri

2018

Gastrointestinal Disorders

View full text Add to dashboard Cite

CC chemokine receptor 6 (CCR6) and its specific partner CC chemokine ligand 20 (CCL20) are known to play a pivotal role in intestinal inflammation. CCR6-associated inflammatory bowel disease (IBD) is already at the forefront of experimental inflammatory disease models, being the subject of numerous analytical studies. IBD is associated with two sub phenotypes, Crohn’s disease (CD) and ulcerative colitis (UC). Both these disease entities produce potent immune dysregulation followed by intense tissue damage within the gut mucosal system, initiating symptoms that are severely debilitating. Multiple causative factors are said to be responsible for IBD, but direct immune dysfunction is kindled by overplay of innate and adaptive immune responses produced against the luminal contents through the weakened or leaky gut epithelial barrier. Once immune homeostasis is not achieved by endogenous protective mechanisms, the self-assertive adaptive immunity mobilizes its various T and B cell cohorts, initializing their immune mechanisms by deploying the immune cells towards the site of infection. CCR6 and its unique solitary ligand CCL20 are small protein molecules that are abundantly expressed by T and B lymphocytes and act as chemotactic immune-modulatory envoys that help in the deployment of the effector lymphocyte arm of the immune system and produce two directly opposing outcomes in IBD. This dichotomous immunity consists of either immune tolerance or inflammation which then develops into a chronic state, remaining unresponsive to inherent immunity or targeted clinical therapy. In this review, we have identified large numbers of experimental studies that have employed both mouse models and clinical subjects spanning a period of nearly two decades and we have clustered these into 13 different groups. This review will provide greater understanding of the CCR6–CCL20 axis in IBD and identify gaps in the literature that can be filled in the future.

show abstract

Expression of CCR6 and CXCR6 by Gut-Derived CD4+/CD8α+ T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases

Cited by 42 publications

References 41 publications

The Prophylactic Use of Bovine Colostrum in a Murine Model of TNBS-Induced Colitis

The Prophylactic Use of Bovine Colostrum in a Murine Model of TNBS-Induced Colitis

Clostridium species as probiotics: potentials and challenges

CCR6–CCL20 Axis in IBD: What Have We Learnt in the Last 20 Years?

Contact Info

Product

Resources

About